Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Adv Ther (Weinh). 2020 Sep 28;4(1):2000088. doi: 10.1002/adtp.202000088

Figure 3.

Figure 3.

Schematic representation of the major classes of technologies used to extend drug residence time in the joint for osteoarthritis: (A) hydrogels, (B) polymeric microparticles, (C) liposomes, (D) polymeric nanoparticles, (E) drug conjugates, and (F) hybrid hydrogel/particle systems.